185.58
price down icon1.33%   -2.51
after-market Dopo l'orario di chiusura: 185.60 0.02 +0.01%
loading
Precedente Chiudi:
$188.09
Aprire:
$184.13
Volume 24 ore:
8.76M
Relative Volume:
1.23
Capitalizzazione di mercato:
$342.01B
Reddito:
$57.37B
Utile/perdita netta:
$4.20B
Rapporto P/E:
78.97
EPS:
2.35
Flusso di cassa netto:
$17.83B
1 W Prestazione:
-4.01%
1M Prestazione:
+5.64%
6M Prestazione:
-6.98%
1 anno Prestazione:
+15.66%
Intervallo 1D:
Value
$181.64
$186.66
Intervallo di 1 settimana:
Value
$181.64
$198.98
Portata 52W:
Value
$153.58
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Nome
Abbvie Inc
Name
Telefono
(847) 932-7900
Name
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Dipendente
50,000
Name
Cinguettio
@abbvie
Name
Prossima data di guadagno
2025-04-25
Name
Ultimi documenti SEC
Name
ABBV's Discussions on Twitter

Confronta ABBV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.58 342.01B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
751.45 681.85B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.66 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.85 291.20B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.13 219.89B 53.22B 12.86B 14.85B 6.39

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Iniziato Cantor Fitzgerald Overweight
2024-12-10 Ripresa BofA Securities Neutral
2024-12-05 Downgrade Daiwa Securities Outperform → Neutral
2024-11-22 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-04 Aggiornamento Argus Hold → Buy
2024-10-17 Iniziato Bernstein Mkt Perform
2024-06-05 Aggiornamento HSBC Securities Hold → Buy
2024-05-17 Iniziato Cantor Fitzgerald Overweight
2024-01-29 Aggiornamento William Blair Mkt Perform → Outperform
2023-12-18 Downgrade HSBC Securities Buy → Hold
2023-12-11 Aggiornamento Goldman Neutral → Buy
2023-11-09 Iniziato Deutsche Bank Hold
2023-10-30 Aggiornamento Barclays Equal Weight → Overweight
2023-10-20 Ripresa UBS Neutral
2023-09-29 Iniziato Raymond James Outperform
2023-07-25 Iniziato William Blair Mkt Perform
2023-07-14 Iniziato HSBC Securities Buy
2023-04-05 Downgrade Argus Buy → Hold
2023-03-01 Iniziato Guggenheim Buy
2023-02-22 Downgrade Wolfe Research Outperform → Peer Perform
2023-02-10 Aggiornamento SVB Securities Underperform → Market Perform
2022-11-18 Iniziato Credit Suisse Outperform
2022-11-08 Downgrade Societe Generale Buy → Hold
2022-08-01 Downgrade Atlantic Equities Overweight → Neutral
2022-05-23 Iniziato SVB Leerink Underperform
2022-05-06 Downgrade Daiwa Securities Outperform → Neutral
2022-04-06 Ripresa Morgan Stanley Overweight
2022-02-28 Downgrade UBS Buy → Neutral
2022-02-03 Reiterato BMO Capital Markets Outperform
2022-02-03 Reiterato Barclays Equal Weight
2022-02-03 Reiterato BofA Securities Neutral
2022-02-03 Reiterato Goldman Neutral
2022-01-13 Iniziato Redburn Buy
2022-01-12 Reiterato BMO Capital Markets Outperform
2021-12-09 Ripresa Wells Fargo Overweight
2021-11-23 Aggiornamento Societe Generale Hold → Buy
2021-07-27 Ripresa Truist Buy
2021-04-07 Ripresa RBC Capital Mkts Outperform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-06-23 Aggiornamento Atlantic Equities Neutral → Overweight
2020-06-09 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-06-02 Aggiornamento Argus Hold → Buy
2020-05-18 Ripresa BofA/Merrill Neutral
2020-05-12 Aggiornamento JP Morgan Neutral → Overweight
2020-05-11 Ripresa Morgan Stanley Overweight
2020-04-20 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-02-06 Iniziato Mizuho Buy
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-12-26 Reiterato Cowen Outperform
2019-09-26 Aggiornamento Citigroup Neutral → Buy
2019-08-20 Aggiornamento Piper Jaffray Neutral → Overweight
2019-06-27 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-06-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-05-28 Iniziato Goldman Neutral
2019-04-29 Aggiornamento BMO Capital Markets Underperform → Market Perform
Mostra tutto

Abbvie Inc Borsa (ABBV) Ultime notizie

pulisher
May 08, 2025

Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.

May 08, 2025
pulisher
May 08, 2025

June 27th Options Now Available For AbbVie - Nasdaq

May 08, 2025
pulisher
May 08, 2025

AbbVie Inc. (ABBV): A Bull Case Theory - MSN

May 08, 2025
pulisher
May 08, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar

May 08, 2025
pulisher
May 07, 2025

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink? - Nasdaq

May 07, 2025
pulisher
May 07, 2025

AbbVie’s Skyrizi leads pharma TV ad rankings for April - Medical Marketing and Media

May 07, 2025
pulisher
May 07, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV - TradingView

May 07, 2025
pulisher
May 07, 2025

AbbVie Files Suit Challenging Tennessee’s Contract Pharmacy Law - Bloomberg Law News

May 07, 2025
pulisher
May 07, 2025

Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com

May 07, 2025
pulisher
May 07, 2025

The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie - Yahoo

May 07, 2025
pulisher
May 07, 2025

Are Wall Street Analysts Predicting AbbVie Stock Will Climb Or Sink? - Barchart.com

May 07, 2025
pulisher
May 06, 2025

If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

AbbVie to Present at the Bank of America Securities Healthcare C - GuruFocus

May 06, 2025
pulisher
May 06, 2025

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? - TradingView

May 06, 2025
pulisher
May 06, 2025

AbbVie to Present at the Bank of America Securities Healthcare Conference - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV St - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security ConcernsiShares Biotechnology ETF (NASDAQ:IBB), AbbVie (NYSE:ABBV) - Benzinga

May 06, 2025
pulisher
May 05, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.

May 05, 2025
pulisher
May 05, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth with a 6.15% Upside Potential - DirectorsTalk Interviews

May 05, 2025
pulisher
May 05, 2025

Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com

May 05, 2025
pulisher
May 04, 2025

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance

May 04, 2025
pulisher
May 03, 2025

Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus

May 03, 2025
pulisher
May 02, 2025

Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq

May 02, 2025
pulisher
May 02, 2025

CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView

May 02, 2025
pulisher
May 02, 2025

Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com

May 02, 2025
pulisher
May 01, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center

May 01, 2025
pulisher
May 01, 2025

AbbVie shares snap seven-session gaining streak - MSN

May 01, 2025
pulisher
May 01, 2025

June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, - GlobeNewswire

May 01, 2025
pulisher
Apr 30, 2025

PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360

Apr 30, 2025
pulisher
Apr 30, 2025

Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com

Apr 30, 2025
pulisher
Apr 30, 2025

FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers

Apr 30, 2025
pulisher
Apr 30, 2025

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com

Apr 30, 2025
pulisher
Apr 29, 2025

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

Why AbbVie Stock Topped the Market Today - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

FDA Approval for AbbVie's Rinvoq (ABBV) in Treating Giant Cell A - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

RINVOQ® Receives U.S. FDA Approval for Giant Cell Arteritis - Investing News Network

Apr 29, 2025

Abbvie Inc Azioni (ABBV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general JNJ
$155.66
price down icon 1.04%
drug_manufacturers_general NVO
$64.85
price down icon 4.00%
drug_manufacturers_general NVS
$110.13
price down icon 1.41%
drug_manufacturers_general MRK
$77.65
price down icon 1.86%
$272.05
price down icon 1.37%
Capitalizzazione:     |  Volume (24 ore):